Biological entities are involved in intricate and complex interactions, in which uncovering the
biological information from the network concepts are of great significance. Benefiting from …

Current efforts in precision oncology largely focus on the benefit of genomics-guided
therapy. Yet, advances in sequencing techniques provide an unprecedented view of the …

Isocitrate dehydrogenases (IDHs) are critical metabolic enzymes that catalyze the oxidative
decarboxylation of isocitrate to α-ketoglutarate (αKG), NAD (P) H, and CO2. IDHs …

Abstract Isocitrate dehydrogenase 1 and 2 (IDH) are mutated in multiple cancers and drive
production of (R)-2-hydroxyglutarate (2HG). We identified a lipid synthesis enzyme [acetyl …

Despite huge efforts made in academic and pharmaceutical worldwide research, current
anticancer therapies achieve effective treatment in a limited number of neoplasia cases only …

Loss of the von Hippel–Lindau (VHL) tumor suppressor is a hallmark feature of renal clear
cell carcinoma. VHL inactivation results in the constitutive activation of the hypoxia-inducible …

While synthetic lethality (SL) holds promise in developing effective cancer therapies, SL
candidates found via experimental screens often have limited translational value. Here we …

Motivation Synthetic lethality (SL) is a promising form of gene interaction for cancer therapy,
as it is able to identify specific genes to target at cancer cells without disrupting normal cells …

Two genes are synthetic lethal if mutations in both genes result in impaired cell viability,
while mutation of either gene does not affect the cell survival. The potential usage of …

Disease-initiating mutations in the transcription factor RUNX1 occur as germline and
somatic events that cause leukemias with particularly poor prognosis. However, the role of …